OncoMatch/Colorectal Cancer (CRC)/HER2 (ERBB2)
Colorectal Cancer (CRC)HER2 (ERBB2) Clinical Trials
HER2 amplification or overexpression occurs in approximately 2–3% of metastatic CRC, more commonly in RAS/BRAF wild-type tumors, and predicts resistance to anti-EGFR antibodies while offering an alternative therapeutic target. The trastuzumab plus tucatinib (MOUNTAINEER) regimen received FDA approval for HER2-positive unresectable/metastatic CRC. Trials investigate trastuzumab deruxtecan, bispecific antibodies, and HER2-directed ADCs.
Top recruiting HER2 (ERBB2) Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Seagen, a wholly owned subsidiary of Pfizer
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
University of Campania Luigi Vanvitelli
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
Peking Union Medical College Hospital